PRA announces the expansion of operations in The Netherlands (NL) and the United Kingdom (UK) to accommodate staff growth and strong client demand for our Phase IIa-IIIB service offerings.
Located in the thriving city of Utrecht, NL, this new Dutch facility will host 20+ employees and is the first PRA office in that region to primarily support Product Registration trials. Staff from our three other NL locations (Groningen, Zuidlaren, and Assen) support early development and lab studies.
Previously, our Product Registration staff members in The Netherlands were either home-based or shared facilities with our Mechelen, Belgium employees. “But to better share best practices among employees, we felt that it was now necessary to provide a permanent office for the increasing Dutch Product Registration team,” said PRA’s Frank van de Wijngaert, Vice President and General Partner.
Also this month, PRA’s 240+ employees in Reading, UK relocated to a larger, PRA-designed facility that offers additional room for increasing headcounts and provides modern facilities for client and project team meetings. The location also offers a first-class business park environment with excellent transportation links.
Since 2009, PRA has opened nine new offices in Europe, demonstrating our commitment to meeting our clients’ diverse needs in a dynamic clinical trials environment.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.